Valuation: VolitionRx Limited

Market Cap 3.68M 3.23M 3.05M 2.78M 5.2M 353M 5.24M 36.48M 14.13M 180M 13.81M 13.51M 579M P/E 2026 *
-0.13x
P/E 2027 * -0.26x
Enterprise Value 3.68M 3.23M 3.05M 2.78M 5.2M 353M 5.24M 36.48M 14.13M 180M 13.81M 13.51M 579M EV / Sales 2026 *
1.35x
EV / Sales 2027 * 0.4x
Free-Float
96.42%
Yield 2026 *
-
Yield 2027 * -
1 day+5.37%
1 week-0.38%
Current month-40.31%
1 month-32.66%
3 months-79.92%
6 months-93.23%
Current year-94.93%
1 week 0.23
Extreme 0.2306
0.26
1 month 0.23
Extreme 0.2306
0.72
Current year 0.23
Extreme 0.2306
7.73
1 year 0.23
Extreme 0.2306
14.8
3 years 0.23
Extreme 0.2306
24.6
5 years 0.23
Extreme 0.2306
82.8
10 years 0.23
Extreme 0.2306
136.8
Manager TitleAgeSince
Chief Executive Officer 55 2011-10-05
Director of Finance/CFO 56 2021-01-31
Chief Tech/Sci/R&D Officer 49 2024-03-31
Director TitleAgeSince
Director/Board Member 55 2011-10-05
Director/Board Member 77 2011-10-05
Director/Board Member 64 2019-10-08
Date Insider Type Main position Quantity % Market Cap. Importance
3/17/26
Concord International, Inc.
OtherCompany 0 0% -
3/17/26 Tax

Executive/Senior Manager

5,251 0.0039%
3/17/26 Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
+5.37%-0.38%-97.84%-98.29% 3.68M
+1.85%+7.32%+444.55%+140.70% 4.98B
-0.47%+2.87%+124.14%+479.33% 4.7B
-6.41%+14.16%+38.42%+102.18% 3.65B
+3.76%+18.30%+328.24%+733.51% 3.29B
+2.50%+13.65%-9.00%-15.09% 2.58B
-4.59%-8.24%+48.11% - 1.72B
-0.58%+0.59%+34.12%+63.46% 1.14B
-0.65%+9.04%+182.53%-18.28% 1.13B
+5.08%+8.18%-25.64%+125.45% 629M
Average +0.54%+6.62%+106.77%+168.11% 2.38B
Weighted average by Cap. -0.24%+8.59%+180.80%+263.82%

Financials

2026 *2027 *
Net sales 2.72M 2.39M 2.26M 2.06M 3.85M 261M 3.88M 27.01M 10.46M 133M 10.23M 10.01M 429M 9.27M 8.14M 7.69M 7M 13.11M 889M 13.21M 91.98M 35.63M 454M 34.82M 34.07M 1.46B
Net income -22.25M -19.53M -18.44M -16.81M -31.46M -2.13B -31.68M -221M -85.47M -1.09B -83.54M -81.74M -3.5B -18.42M -16.16M -15.26M -13.91M -26.04M -1.77B -26.23M -183M -70.75M -902M -69.16M -67.66M -2.9B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
26-09-25 US$0.2590 +5.37% 2,891,479
26-09-24 US$0.2458 -0.49% 893,491
26-09-23 US$0.2470 -6.16% 2,842,679
26-09-22 US$0.2632 -0.64% 1,717,967
26-09-21 US$0.2649 +1.88% 1,859,474
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2590USD
Average target price
13.62USD
Spread / Average Target
+5,159.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock